IgD Chain Inhibitors
the chemical class of IgD Chain Inhibitors. This class encompasses a diverse range of small molecule compounds that target various components of the B cell receptor signaling pathway, ultimately leading to inhibition of IgD activation and B cell function. One major category includes inhibitors of kinases such as Bruton's tyrosine kinase (BTK), Janus kinases (JAKs), and spleen tyrosine kinase (SYK), which are critical for transmitting signals downstream of the IgD receptor. Compounds like Acalabrutinib, Ibrutinib, and R406 selectively target these kinases, disrupting their activity and preventing IgD-mediated responses.
Another subset of IgD Chain Inhibitors includes compounds that target phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), key regulators of B cell receptor signaling pathways. Idelalisib, Everolimus, and Cal-101 inhibit specific isoforms of PI3K, while Everolimus also targets mTOR, leading to inhibition of downstream signaling events associated with IgD activation. Additionally, compounds like Venetoclax modulate apoptotic pathways in B cells by targeting B cell lymphoma 2 (BCL-2), thereby influencing IgD-dependent responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib inhibits Bruton's tyrosine kinase (BTK), a key enzyme involved in B cell receptor signaling pathways, thereby preventing IgD activation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib irreversibly inhibits BTK, disrupting downstream signaling pathways essential for IgD function and B cell activation. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $189.00 | 4 | |
Idelalisib is a selective inhibitor of phosphoinositide 3-kinase (PI3K), a kinase involved in B cell receptor signaling, leading to suppression of IgD-mediated responses. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits multiple tyrosine kinases, including Src family kinases, which are involved in B cell receptor signaling and IgD activation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib targets Janus kinases (JAKs), which play a role in B cell receptor signaling cascades, thereby interfering with IgD-mediated responses. | ||||||
KY02111 | 1118807-13-8 | sc-397043 sc-397043A | 5 mg 25 mg | $79.00 $336.00 | ||
Entospletinib is a selective inhibitor of spleen tyrosine kinase (SYK), which regulates B cell receptor signaling and downstream IgD activation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits mammalian target of rapamycin (mTOR), a kinase involved in B cell receptor signaling pathways, thereby modulating IgD function. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 targets B cell lymphoma 2 (BCL-2), which regulates apoptotic pathways in B cells, influencing IgD-dependent responses. | ||||||
P276-00 | 920113-03-7 | sc-477932 | 1 mg | $380.00 | ||
R406 inhibits SYK, an enzyme downstream of B cell receptor activation, thereby attenuating IgD-mediated signaling cascades. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $311.00 | ||
Duvelisib inhibits PI3K-delta and PI3K-gamma isoforms, which regulate B cell receptor signaling, affecting IgD-mediated responses. | ||||||